603 related articles for article (PubMed ID: 1086218)
1. "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell.
Kiessling R; Klein E; Pross H; Wigzell H
Eur J Immunol; 1975 Feb; 5(2):117-21. PubMed ID: 1086218
[TBL] [Abstract][Full Text] [Related]
2. Five types of lymphocytes (Ig-theta-, Ig-theta+weak, Ig-theta+strong, Ig+theta- and Ig+theta+) characterized by double immunofluorescence and electrophoretic mobility. Organ distribution in normal and nude mice.
Roelants GE; Loor F; von Boehmer H; Sprent J; Hägg LB; Mayor KS; Rydén A
Eur J Immunol; 1975 Feb; 5(2):127-31. PubMed ID: 1086220
[TBL] [Abstract][Full Text] [Related]
3. IgM antibody-dependent cell-mediated cytotoxicity in the Moloney sarcoma virus system: the involvement of T and B lymphocytes as effector cells.
Lamon EW; Whitten HD; Skurzak HM; Andersson B; Lidin B
J Immunol; 1975 Nov; 115(5):1288-94. PubMed ID: 1080777
[TBL] [Abstract][Full Text] [Related]
4. Influence of genotype and the organ of origin on the subtype of T-cell in Moloney lymphomas induced by transfer of preleukemic cells from athymic and thymus-bearing mice.
Asjö B; Skoog L; Palminger I; Wiener F; Isaak D; Cerny J; Fenyö EM
Cancer Res; 1985 Mar; 45(3):1040-5. PubMed ID: 3871660
[TBL] [Abstract][Full Text] [Related]
5. Suppression of natural killer cell activity with radioactive strontium: effector cells are marrow dependent.
Haller O; Wigzell H
J Immunol; 1977 Apr; 118(4):1503-6. PubMed ID: 300411
[TBL] [Abstract][Full Text] [Related]
6. The influence of cyclophosphamide on antibody formation in the mouse.
Willers JM; Sluis E
Ann Immunol (Paris); 1975 Apr; 126(3):267-79. PubMed ID: 1101799
[TBL] [Abstract][Full Text] [Related]
7. Natural immunity to grafts of FLD-3 erythroleukemia cells by irradiated mice.
Afifi MS; Bennett M; Kumar V
Nat Immun Cell Growth Regul; 1986; 5(4):200-10. PubMed ID: 2430178
[TBL] [Abstract][Full Text] [Related]
8. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
9. Cell-mediated immunity to leukemia virus- and tumor-associated antigens in mice.
Herberman RB; Holden HT; Ting CC; Lavrin DL; Kirchner H
Cancer Res; 1976 Feb; 36(2 pt 2):615-21. PubMed ID: 56223
[TBL] [Abstract][Full Text] [Related]
10. Cell interactions in leukemia-associated immunosuppression: suppression of thymus-independent antibody responses by leukemia spleen cells (Moloney) in vitro is mediated by normal T cells.
Caulfield MJ; Cerny J
J Immunol; 1980 Jan; 124(1):255-60. PubMed ID: 6965291
[No Abstract] [Full Text] [Related]
11. T lymphocyte tolerance and early appearance of virus-induced cell surface antigens in Moloney-murine leukemia virus neonatally injected mice.
Collavo D; Zanovello P; Biasi G; Chieco-Bianchi L
J Immunol; 1981 Jan; 126(1):187-93. PubMed ID: 6969741
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppression in a murine B cell leukemia (BCL1): role of an adherent cell in the suppression of primary in vitro antibody responses.
Anderson SA; Isakson PC; Puré E; Muirhead M; Uhr JW; Vitetta ES
J Immunol; 1981 Apr; 126(4):1603-7. PubMed ID: 6451649
[TBL] [Abstract][Full Text] [Related]
13. Genetic control of sensitivity to moloney leukemia virus in mice. VI. Involvement of virus-specific T helper cells collaborating with B cells.
Boyer B; Debré P; Seman M; Zilberfarb V; Lévy JP
Eur J Immunol; 1982 Aug; 12(8):692-7. PubMed ID: 6216112
[TBL] [Abstract][Full Text] [Related]
14. Functional activity in vivo of effector T cell populations. III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clone.
Cerundolo V; Lahaye T; Horvath C; Zanovello P; Collavo D; Engers HD
Eur J Immunol; 1987 Feb; 17(2):173-8. PubMed ID: 3030766
[TBL] [Abstract][Full Text] [Related]
15. Use of adoptive transfer and Winn assay procedures in the further analysis of antiviral acquired immunity in mice protected against Friend leukemia virus-induced disease by passive serum therapy.
Genovesi EV; Pettey CL; Collins JJ
Cancer Res; 1984 Apr; 44(4):1489-98. PubMed ID: 6608407
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic T cell response against lymphoblasts infected with Moloney (Abelson) murine leukemia virus. Methodological aspects and H-2 requirements.
Stukart MJ; Vos A; Melitef CJ
Eur J Immunol; 1981 Mar; 11(3):251-7. PubMed ID: 6972310
[TBL] [Abstract][Full Text] [Related]
17. Cell surface expression of cytotoxic T lymphocyte-defined, AKR/Gross leukemia virus-associated tumor antigens by normal AKR.H-2b splenic B cells.
Green WR
J Immunol; 1983 Dec; 131(6):3078-84. PubMed ID: 6605998
[TBL] [Abstract][Full Text] [Related]
18. Cell-mediated immunity to Friend virus-induced leukemia. III. Characteristics of secondary cell-mediated cytotoxic response.
Ting CC; Kirchner H; Rodrigues D; Park JY; Herberman RB
J Immunol; 1976 Jan; 116(1):244-52. PubMed ID: 54388
[TBL] [Abstract][Full Text] [Related]
19. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia.
Gregg EO; Gregg IC; Green I
Cancer Res; 1987 Feb; 47(3):723-9. PubMed ID: 3492265
[TBL] [Abstract][Full Text] [Related]
20. Production of BSF-1 during an in vivo, T-dependent immune response.
Finkelman FD; Ohara J; Goroff DK; Smith J; Villacreses N; Mond JJ; Paul WE
J Immunol; 1986 Nov; 137(9):2878-85. PubMed ID: 3489779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
